Introduction {#Sec1}
============

The addition of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) to basal insulin in patients with type 2 diabetes (T2D) who are unable to achieve and/or sustain adequate control of glycated hemoglobin A1c (A1C) is an important treatment option. Treatment with a GLP-1 RA and basal insulin has a favorable adverse event (AE) profile and comparable A1C reduction, with lower rates of documented symptomatic hypoglycemia (plasma glucose ≤ 70 mg/dL) and greater weight loss compared with treatment intensification with prandial insulin \[[@CR1]--[@CR7]\]. Real-world evidence has shown that escalation of therapy beyond basal insulin often takes a median time of 3.7 years, and only occurs in 31% of eligible patients \[[@CR8]\]. In addition, if patients have not achieved a glycemic target of less than 7.0% at 12 months on basal insulin, the conditional probability of achieving glycemic goals thereafter drops substantially \[[@CR9]\]. The American Diabetes Association/European Association for the Study of Diabetes guidelines suggest that when basal insulin is insufficient to achieve control in T2D patients, GLP-1 RAs and rapid-acting insulins are the agents most commonly added to achieve glycemic control \[[@CR5]\]. Typically, as treatment regimens become more complex, there is increased potential for drug-specific side effects to occur. This, combined with patient fears of weight gain, hypoglycemia, increased injection burden, and associated pain, often leads to failure to intensify therapy, treatment non-adherence, and glycemic targets not being reached \[[@CR10], [@CR11]\]. These factors may be addressed with the use of titratable fixed-ratio combinations (FRCs), as the complications associated with use of the individual components can be minimized \[[@CR12]\].

iGlarLixi (Soliqua 100/33^®^/Suliqua^®^) is a titratable FRC of insulin glargine 100 units/mL (Lantus^®^ \[referred to as insulin glargine in the remainder of this paper\]) and the GLP-1 RA lixisenatide (33 μg/mL; Adlyxin^®^/Lyxumia^®^) \[[@CR13]--[@CR15]\], delivered as a once-daily subcutaneous injection, which was approved for use in the USA (Soliqua 100/33^®^) in November 2016 and in Europe (Suliqua^®^) in January 2017 \[[@CR15]--[@CR17]\]. The safety of the two individual components is well established in T2D. The landmark ORIGIN trial showed that insulin glargine does not influence the occurrence of cardiovascular events and only resulted in a small number of hypoglycemia episodes and slight weight gain \[[@CR18]\]. Similarly, the ELIXA trial found that the addition of lixisenatide to usual care in patients with T2D and acute coronary syndrome within 180 days of an event had a neutral effect on cardiovascular outcomes, with no difference in the rates of serious AEs or severe hypoglycemia compared with placebo \[[@CR19]\].

This review discusses the safety profile and AEs associated with iGlarLixi and the individual components in the FRC using data reported in key clinical cardiovascular outcome trials, such as ORIGIN and ELIXA.

iGlarLixi Clinical Development Program {#Sec2}
--------------------------------------

The rationale for combining insulin glargine and lixisenatide in the same titratable FRC lies in their complementary mechanisms of action. According to DeFronzo et al., the combination of insulin and a GLP-1 RA targets seven of the eight pathophysiologic defects which lead to hyperglycemia \[[@CR20]\]. Insulin glargine primarily reduces hepatic glucose production and increases glucose uptake in skeletal muscle and adipose tissues, lowering fasting plasma glucose levels. Lixisenatide primarily acts through a delay in gastric emptying; it increases glucose-dependent insulin secretion and decreases glucagon, which results in reduced prandial glycemic excursion \[[@CR5], [@CR21], [@CR22]\]. The complementary actions of both agents are summarized in Fig. [1](#Fig1){ref-type="fig"} \[[@CR23]\]. The most common AE associated with insulin glargine is hypoglycemia, while those most commonly associated AEs with lixisenatide are gastrointestinal (GI)-related \[[@CR24]--[@CR26]\], with other events less commonly related.Fig. 1iGlarLixi combines the complementary actions of insulin glargine (which targets fasting plasma glucose) and lixisenatide (which targets postprandial glucose).Adapted from Rosenstock et al. \[[@CR23]\]

The efficacy and safety of iGlarLixi was first demonstrated in a phase 2, 24-week, randomized, open-label, active-controlled, proof-of-concept study \[[@CR23]\], which compared the combination of insulin glargine and lixisenatide with insulin glargine in insulin-naïve adults with T2D inadequately controlled on metformin. The combination consisted of insulin glargine and lixisenatide in a 2:1 ratio (at a maximum dose of insulin glargine 60 units/day and lixisenatide 30 µg/day) compared with insulin glargine alone with no upper limit on the dose of insulin glargine. In this study, iGlarLixi significantly reduced A1C to a greater extent compared with insulin glargine alone, with comparable rates of hypoglycemia and significant weight loss. Two subsequent open-label, randomized, parallel-group, multicenter, phase 3 trials, LixiLan-L \[[@CR14]\] and LixiLan-O \[[@CR13]\], further demonstrated the efficacy and safety of iGlarLixi. In these trials, the maximum dose of insulin glargine was capped to 60 units/day, with the insulin glargine to lixisenatide ratios being either 2:1 (Pen A) or 3:1 (Pen B). The primary efficacy endpoint was change in A1C from baseline to week 30 in both trials. Both trials also had a run-in period, either optimizing the glargine dose (LixiLan-L) or metformin dose (LixiLan-O), prior to randomization. LixiLan-L compared iGlarLixi with insulin glargine in patients inadequately controlled on basal insulin with or without up to two oral antidiabetes drugs (OADs). In LixiLan-L, iGlarLixi showed greater reductions in A1C from baseline compared with insulin glargine alone (− 1.1% vs − 0.6%, *P* \< 0.0001) and significantly more patients treated with iGlarLixi reached a target A1C of less than 7.0% (55% vs 30%, respectively; *P* \< 0.001). In addition, iGlarLixi was superior to insulin glargine in achieving the composite endpoint of A1C \< 7.0% with no weight gain and with no documented symptomatic hypoglycemia (20% vs 9%, respectively; *P* \< 0.001) at week 30 \[[@CR14]\]. LixiLan-O compared iGlarLixi with its components insulin glargine or lixisenatide in patients inadequately controlled on metformin, with or without a second OAD, which was subsequently discontinued. As in LixiLan-L, greater reductions in A1C from baseline were achieved with iGlarLixi compared with insulin glargine (− 1.6% vs − 1.3%, respectively; *P* \< 0.0001) and significantly more patients treated with iGlarLixi compared with insulin glargine achieved target A1C \< 7.0% (74% vs 59%, respectively; *P* \< 0.0001) and met the composite endpoint of A1C \< 7.0% with no weight gain and with no documented symptomatic hypoglycemia (32% vs 19%, respectively; *P* \< 0.0001). iGlarLixi also induced fewer GI AEs compared with lixisenatide alone (27.1% vs 36.9%, respectively) \[[@CR13]\]. As one might expect, patients in the LixiLan-L study had different characteristics to those in the LixiLan-O study, such as a longer duration of diabetes (mean duration 12 years and 8.8 years, respectively) and more advanced disease requiring basal insulin treatment \[[@CR13], [@CR14]\]. Overall, the LixiLan studies demonstrated that iGlarLixi significantly improved glycemic control compared with the individual components, with a risk of hypoglycemia comparable to insulin glargine, mitigation of weight gain compared with insulin glargine, and reduced GI AEs compared with lixisenatide.

Methods {#Sec3}
=======

In this review, we collated patient-level data from the LixiLan proof-of-concept trial, the LixiLan-L trial, and the LixiLan-O trial to evaluate AEs associated with iGlarLixi treatment \[[@CR13], [@CR14], [@CR23]\]. A pool of 2222 patients from the LixiLan phase 2/3 studies was used to summarize malignancies, renal AEs, and AEs adjudicated as allergic reactions, major cardiovascular events, injection site reactions, and thyroid disorders. A pool of 1899 patients from the LixiLan phase 3 trials was the primary basis to describe the overall treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs leading to treatment discontinuation, and adjudicated pancreatic events. The LixiLan-L and LixiLan-O trials were used separately to provide an overview of hypoglycemia rates. We also describe data from the ELIXA study to determine the incidence of pancreatitis and pancreatic cancer, and the ORIGIN and ELIXA studies for cardiovascular safety data \[[@CR18], [@CR19]\]. Data reported in this review was collated from studies for which all data is available in the public domain; no novel data was generated.

Results and Discussion {#Sec4}
======================

Safety of iGlarLixi {#Sec5}
-------------------

A summary of the AEs reported in the iGlarLixi phase 3 clinical trials is provided in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} \[[@CR27]\].Table 1iGlarLixi TEAEs in pooled data from the phase 3 LixiLan studies \[[@CR27]\]Phase 3 study dataLixiLan-OiGlarLixi (*n* = 834)Insulin glargine (*n* = 832)Lixisenatide (*n* = 233)Any TEAE, *n* (%)462 (55.4)418 (50.2)157 (67.4)Serious TEAE, *n* (%)38 (4.6)37 (4.4)9 (3.9)Any TEAE leading to death, *n* (%)3 (0.4)5 (0.6)1 (0.4)Any TEAE leading to permanent discontinuation, *n* (%)22 (2.6)12 (1.4)21 (9.0)*n (%)* number and percentage of patients with at least one TEAE, *TEAE* treatment-emergent adverse event Table 2iGlarLixi: TEAEs leading to treatment discontinuation in the phase 3 controlled studies \[[@CR27]\]Phase 3 study dataLixiLan-OiGlarLixi (*n* = 834)Insulin glargine (*n* = 832)Lixisenatide (*n* = 233)Gastrointestinal TEAEs, *n* (%)8 (1.0)1 (0.1)12 (5.2) Nausea, *n* (%)6 (0.7)06 (2.6) Vomiting, *n* (%)2 (0.2)04 (1.7) Diarrhea, *n* (%)1 (0.1)02 (0.9)Skin and subcutaneous disorders, *n* (%)4 (0.5)1 (0.1)1 (0.4) Urticaria, *n* (%)3 (0.4)01 (0.4)Preferred terms with two or more patients in any treatment group*n (%)* number and percentage of patients with at least one TEAE, *TEAE* treatment-emergent adverse event

Hypoglycemia {#Sec6}
------------

Hypoglycemia is one of the most common AEs in patients receiving insulin therapies \[[@CR28]\], and poses a major barrier to insulin initiation and treatment intensification. Fear of hypoglycemia often leads to treatment discontinuation, further contributing to suboptimal glycemic control. Hypoglycemia rates reported in clinical trials vary depending on definition of hypoglycemia used, duration of T2D, patient age, renal function, insulin dose, fasting plasma glucose target, intensity of glucose control and background therapy, meaning comparisons between studies can be inconclusive \[[@CR28]\]. Therefore, this section discusses the rates of hypoglycemia reported in LixiLan-L and LixiLan-O trials separately.

The incidence of documented symptomatic hypoglycemia (plasma glucose ≤ 70 mg/dL) in patients receiving iGlarLixi was 40.0% in the LixiLan-L trial and 25.6% in LixiLan-O trial (Table [3](#Tab3){ref-type="table"}), which compared favorably with the incidence of documented symptomatic hypoglycemia in patients treated with insulin glargine alone (LixiLan-L, 42.5%; LixiLan-O, 23.6%) \[[@CR13], [@CR14]\]. Consequently, the number of patients experiencing hypoglycemia within each trial was no higher with iGlarLixi compared with insulin glargine alone, despite a lower A1C in the iGlarLixi groups. The higher incidence of hypoglycemia observed in the LixiLan-L study is likely due to patients having a longer duration of diabetes and longer duration of insulin treatment \[[@CR29]\]. In the LixiLan-L trial, the rate of hypoglycemia events was lower with iGlarLixi compared with insulin glargine alone (3.03 vs 4.22 events per patient year, respectively) and was similar between iGlarLixi and insulin glargine alone in LixiLan-O (1.4 vs 1.2 events per patient-year, respectively). These data demonstrate that the risk of symptomatic documented hypoglycemia in patients receiving insulin glargine in combination with lixisenatide (i.e., as iGlarLixi) is lower or comparable to that in patients receiving insulin glargine alone.Table 3Hypoglycemia events in the LixiLan-O and LixiLan-L trialsLixiLan-OLixiLan-LiGlarLixi (*n* = 469)Insulin glargine (*n* = 467)Lixisenatide (*n* = 233)iGlarLixi (*n* = 365)Insulin glargine (*n* = 365)Documented symptomatic hypoglycemia (PG ≤ 70 mg/dL \[3.9 mmol/L\]) *n* (%)120 (25.6)110 (23.6)15 (6.4)146 (40.0)155 (42.5) Events per patient-year1.41.20.33.034.22Severe symptomatic hypoglycemia *n* (%)01 (0.2)04 (1.1)1 (0.3) Events per patient-year0\< 0.0100.02\< 0.01*PG* plasma glucose

The incidence of severe hypoglycemia (an event requiring third-party assistance) was generally low in both the LixiLan-L trial (*n* = 4 \[1.1%\] and *n* = 1 \[0.3%\] for the iGlarLixi arm and insulin glargine arm, respectively) and in the LixiLan-O trial (*n* = 0 \[0.0%\], *n* = 1 \[0.2%\], *n* = 0 \[0.0%\] in the iGlarLixi, insulin glargine, and lixisenatide arms, respectively) \[[@CR13], [@CR14]\].

Gastrointestinal Tolerability {#Sec7}
-----------------------------

Overall, the LixiLan trials demonstrated a low incidence of GI AEs with low rates of permanent treatment discontinuation when utilizing iGlarLixi compared with lixisenatide alone \[[@CR30]\]. The GI events that did arise were mainly mild to moderate in severity, transient, and occurred primarily during the first 8 weeks of treatment \[[@CR13], [@CR14]\]. The rates of GI AEs in patients treated with iGlarLixi were lower than those treated with lixisenatide alone, while rates of GI AEs in patients treated with insulin glargine alone were predictably lower than in patients treated with iGlarLixi \[[@CR13]\].

In the LixiLan-L trial, GI AEs occurred in 17.0% of patients receiving iGlarLixi compared with 7.9% of patients treated with insulin glargine. These AEs were generally mild, with nausea occurring in 10.4% of patients (vs 0.5% insulin glargine), diarrhea in 4.4% of patients (vs 2.7% insulin glargine), and vomiting in 3.6% (vs 0.5% insulin glargine) \[[@CR14]\]. In the LixiLan-O trial, the incidence of GI AEs was 21.7% among patients treated with iGlarLixi compared with 12.6% of patients treated with insulin glargine and 36.9% for patients treated with lixisenatide. Nausea was the most common GI AE experienced with iGlarLixi occurring in 9.6% of patients (vs 3.6% insulin glargine, vs 24.0% lixisenatide), 9.0% experiencing diarrhea (vs 4.3% insulin glargine, vs 9.0% lixisenatide), and 3.2% experiencing vomiting (vs 1.5% insulin glargine, vs 6.4% lixisenatide) \[[@CR13]\].

The rates of treatment discontinuation due to GI AEs were low in both trials. In LixiLan-L, treatment discontinuation due to GI AEs was observed in 1.1% of patients and was exclusively due to nausea \[[@CR14]\]. No GI AEs associated with insulin glargine resulted in treatment discontinuation. In LixiLan-O, treatment discontinuation resulting from GI AEs occurred in 1.0% of iGlarLixi-treated patients overall, with 0.4% of patients discontinuing due to nausea (vs 2.6% lixisenatide), 0.4% due to vomiting (vs 1.7% lixisenatide), and 0.2% due to diarrhea (vs 0.9% lixisenatide) \[[@CR13]\]. No GI AEs associated with insulin glargine resulted in treatment discontinuation \[[@CR13]\].

The gradual dose increase of lixisenatide occurring simultaneously with up-titration of insulin glargine could explain the lower incidence of GI AEs observed with iGlarLixi when compared with lixisenatide alone \[[@CR27]\]. Incidences of nausea and vomiting per week in iGlarLixi vs insulin glargine in LixiLan-L and vs lixisenatide in LixiLan-O, over 30 weeks, are shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Incidence of nausea and vomiting per week with iGlarLixi vs. iGlar in LixiLan-L (**a**) and vs. lixisenatide in LixiLan-O (**b**)

Immunogenicity {#Sec8}
--------------

The synthetic proteins used in the treatment of T2D often activate an immunologic response that results in the production of anti-drug antibodies (ADAs) in patients undergoing treatment. Severe immunologic complications are rare, and although there have been some reports that ADAs can affect glycemic control, the majority of clinical trial data suggest otherwise \[[@CR31]\]. The measurement of ADAs is routine in T2D clinical trials, to establish whether or not antibody positivity influences the safety and efficacy of the product. However, incidence rates can vary widely between products, and it is often difficult to perform a direct comparison of ADA incidence because of differences in the methodology and interpretation of data, the product, and the patient population \[[@CR32]\]. In the LixiLan-O study, 21% of patients treated with iGlarLixi and 8.9% of patients that received insulin glargine were positive for anti-insulin glargine antibodies after 30 weeks of treatment; while in the LixiLan-L study, the incidence was comparable between the iGlarLixi (26.2%) and insulin glargine (24.8%) treatment groups \[[@CR27]\]. There were no substantial differences noted in the efficacy or safety profiles of the antibody-positive and antibody-negative patient populations (for both anti-insulin glargine and anti-lixisenatide patients) in either of the iGlarLixi phase 3 trials \[[@CR13], [@CR14]\].

Hypersensitivity Reactions {#Sec9}
--------------------------

### Local and Injection-Site Reactions {#Sec10}

As with any subcutaneous injected peptide, injection-site reactions, including hematoma, pain, hemorrhage, erythema, swelling, and pruritus may be experienced. In the phase 2/3 study pool, 1.7% of patients receiving iGlarLixi and 1.1% of patients receiving insulin glargine alone experienced an injection-site reaction. These events were generally mild, with one patient reporting a moderate event in each group \[[@CR27]\].

### Allergic Reactions {#Sec11}

Subcutaneously injected synthetic peptides, such as GLP-1 RAs, have the potential to cause allergic reactions \[[@CR33]\]. For iGlarLixi development, the Allergic Reaction Assessment Committee (ARAC) reviewed all investigator-reported allergic reaction events in a blinded manner, using stringent criteria to determine the severity of the event and whether or not it was related to the study drug. In the phase 3 LixiLan studies, the number of iGlarLixi-treated patients with an event adjudicated by the ARAC as an allergic reaction was 7 (0.7%) in the iGlarLixi group, 5 (0.5%) in the insulin glargine group, and 2 (0.9%) in the lixisenatide group \[[@CR27]\]. The majority of patients (9/14) had events that were assessed as not related to study drug. In LixiLan-O, there were 3 (0.3%) patients in the iGlarLixi arm, no patients in the insulin glargine arm, and 2 (0.9%) patients in the lixisenatide arm with events adjudicated as an allergic reaction possibly related to study drug. All events were graded moderate in severity \[[@CR27]\].

Pancreatitis {#Sec12}
------------

The use of GLP-1 RAs has been associated with a risk of developing acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis \[[@CR34]\]. In the phase 3 LixiLan studies, there were no reported episodes of pancreatitis \[[@CR13], [@CR14], [@CR27]\]. Low overall rates of pancreatitis in patients receiving either lixisenatide or placebo were also reported in the ELIXA study (for patients receiving at least one dose of lixisenatide, *n* = 3031; or placebo, *n* = 3032, median follow-up period 25 months), with a lower incidence of pancreatitis in the lixisenatide group (*n* = 5; 0.2%) compared with the placebo group (*n* = 8; 0.3%) \[[@CR19], [@CR27]\].

Malignancy {#Sec13}
----------

### Pancreatic and Other Cancers {#Sec14}

It remains controversial whether or not GLP-1 RA-based therapies increase the risk of developing specific malignant diseases, such as pancreatic carcinoma or thyroid cancer. In a study by Elashoff et al., which analyzed the US Food and Drug Administration (FDA)'s database of reported AEs associated with the GLP-1 RA exenatide, they found the human data to be consistent with animal data, showing that GLP-1 RA therapies were associated with an increased risk of pancreatitis \[[@CR34]\]. Since pancreatitis is a risk factor for pancreatic cancer, there was a concern that chronic use of GLP-1 RA-based therapies might therefore be a risk factor for pancreatic cancer in the long term \[[@CR34]\]. However, it has been suggested that this analysis was limited by a reporting bias and, therefore, provides insufficient evidence to make this association \[[@CR35]\]. Potential malignant pancreatic events and other cancers were also assessed for causality by an adjudication committee for the LixiLan studies (iGlarLixi vs insulin glargine) and the ELIXA trial (lixisenatide vs placebo) specifically \[[@CR27]\]. Similar to the incidence of pancreatitis in the LixiLan trials, the incidence of pancreatic cancer was also low. There was a single case of malignant pancreatic neoplasm reported for the insulin glargine group in LixiLan-O that led to permanent treatment discontinuation, but this case was found to be unrelated to the study drug; there were no incidences of pancreatic cancer in the groups receiving iGlarLixi or lixisenatide \[[@CR13], [@CR27]\]. A key constraint of the LixiLan trials was their relatively short duration (30 weeks), though this has been solved by the longer-term ELIXA cardiovascular outcomes trials.

The ELIXA study (lixisenatide, *n *= 3031; placebo, *n* = 3032), conducted over a median follow-up period of 25 months, confirmed the low rate of malignant pancreatic neoplasms reported in 3 (\< 0.1%) patients treated with lixisenatide compared to 9 (0.3%) patients receiving placebo, a similar imbalance to that seen with cases of pancreatitis in favor of lixisenatide \[[@CR27]\].

### Thyroid Malignancy {#Sec15}

In a filing to the FDA, thyroid tumors were reported to be increased in rodents treated with liraglutide and other long-acting GLP-1 RAs \[[@CR36]\]. As a result of this preclinical evidence, the use of liraglutide, exenatide extended-release, dulaglutide, and semaglutide is contraindicated in patients with a personal or family history of thyroid carcinoma, and the prescribing information for these long-acting GLP-1 RAs includes a black-box warning in the USA for risk of thyroid C cell tumors \[[@CR37]--[@CR40]\]. However, as is the case for pancreatic cancer, the evidence supporting the hypothesis that GLP-1 RAs cause (medullary) thyroid cancer is insufficient \[[@CR35]\]. To date, no cases of thyroid carcinoma have been identified from clinical trials or through post-marketing surveillance for patients treated with iGlarLixi. Additionally, there were no clinically significant changes in mean calcitonin levels related to treatment with iGlarLixi during the clinical trial program \[[@CR27]\].

Renal Function {#Sec16}
--------------

In the USA and other western countries, T2D is recognized as a leading cause of chronic kidney disease and end-stage renal disease \[[@CR41]\]. Acute kidney injury and worsening of chronic renal failure (which are generally due to GI AEs and dehydration \[[@CR42]\]) have been observed in patients treated with GLP-1 RAs, such as lixisenatide. These events were also found in patients without any known renal disease \[[@CR15]\].

Analysis of pooled data from the LixiLan trials showed that during the on-treatment period, similar proportions of patients treated with iGlarLixi and those treated with insulin glargine had mild and moderate renal impairment based upon creatinine clearance. There were no patients with severe renal impairment in the iGlarLixi or lixisenatide groups, while the proportion was low in the insulin glargine group (0.2%) \[[@CR27]\]. A post hoc analysis from the ELIXA trial in patients with T2D without severe renal impairment (estimated glomerular filtration rate \[eGFR\] \> 30 mL/min/1.73 m^2^), but with a recent acute coronary syndrome event, demonstrated that the addition of lixisenatide to usual care improved the burden of micro- and macroalbuminuria beyond glycemic control (reduction in urinary albumin/creatinine ratio) \[[@CR43]\]. In the LixiLan trials, patients with an eGFR \< 30 mL/min were excluded from participation (considered severe renal impairment to end-stage chronic kidney disease).

The incidence of common TEAEs in the iGlarLixi and insulin glargine treatment groups was similar in both patients with normal renal function (53.8% iGlarLixi vs 48.5% insulin glargine) and in patients with mild renal impairment at baseline for the phase 3 study pool (56.5% iGlarLixi vs 54.0% insulin glargine) \[[@CR27]\].

Cardiovascular Safety {#Sec17}
---------------------

In 2008, the FDA recommended that all new antihyperglycemic medications being investigated for the treatment of T2D should be evaluated for cardiovascular AEs \[[@CR44]\]. In the LixiLan trials, the Cardiovascular Events Adjudication Committee, which comprised cardiovascular and cerebrovascular disease experts independent of the sponsor and the investigators, was set up to adjudicate cardiovascular endpoints in a blinded manner. A cardiovascular outcome trial was not required for iGlarLixi since the lixisenatide and insulin glargine components had each been evaluated for cardiovascular outcomes in the ELIXA and ORIGIN trials, respectively. The LixiLan trials were, therefore, not powered to specifically assess cardiovascular outcomes. However, data from these trials showed that the incidence of cardiovascular events in patients treated with iGlarLixi was low and comparable to that observed in patients taking insulin glargine \[[@CR13], [@CR14]\].

The ELIXA study included 6068 patients who had experienced an acute coronary syndrome event (acute myocardial infarction \[MI\] or hospitalization for MI) within the previous 180 days, representing a relatively unstable population at particularly high cardiovascular risk \[[@CR19]\]. Over a median follow-up of 25 months, the composite primary endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, and hospitalization for unstable angina (4-point major adverse cardiovascular event) was comparable between patients receiving lixisenatide (13.4%) and those receiving placebo (13.2%). Hospitalization rates for heart failure were comparable between the two groups (hazard ratio, 0.96; 95% confidence interval \[CI\], 0.75--1.23), as were rates of death (hazard ratio 0.94; 95% CI 0.78--1.13) \[[@CR19]\].

The ORIGIN trial \[[@CR45]\] demonstrated that there was no increased risk of cardiovascular events associated with insulin glargine in patients with prediabetes or early T2D and high cardiovascular risk. Additionally, there was no association with increased risk of serious cardiovascular events in individuals with pre-existing cardiovascular risk factors compared with standard of care. Rates of cardiovascular events were similar with insulin glargine and standard care (2.94 and 2.85 per 100 person-years, respectively).

Adverse Events in Specific Populations {#Sec18}
--------------------------------------

### Older Patients {#Sec19}

In older patients (≥ 65 years), a post hoc analysis of data from the LixiLan-L and LixiLan-O trials showed that iGlarLixi was associated with no increased risk of hypoglycemia when compared with insulin glargine. Modest weight loss was observed in iGlarLixi-treated older patients in both the LixiLan-L (*P* = 0.007) and LixiLan-O (*P* = 0.017) trials \[[@CR46]\]. Of the 834 patients in the LixiLan studies who received iGlarLixi, 25.2% (*n* = 210) were at least 65 years of age and 4% (*n* = 33) were at least 75 years of age. Overall, there was no difference in safety and efficacy of iGlarLixi observed across the age groups \[[@CR15]\].

### Gender {#Sec20}

A further post hoc analysis of the LixiLan trials found no differences in the effects of iGlarLixi based on gender \[[@CR47]\].

### Children and Pregnancy {#Sec21}

To date, the use of iGlarLixi, or its components, has not been studied in children with T2D or during pregnancy \[[@CR15], [@CR25], [@CR26]\]. It is currently recommended that iGlarLixi should not be used during pregnancy unless the potential benefits outweigh the potential risks to the developing fetus.

Summary {#Sec22}
=======

Treatment with insulin and a GLP-1 RA targets seven of the eight pathophysiologic defects which lead to hyperglycemia in T2D \[[@CR20]\]. The complementary actions of insulin glargine and lixisenatide have been shown to exert beneficial effects on A1C, with no increased risk of hypoglycemia, while also reducing body weight compared with insulin glargine alone, and with fewer GI side effects than lixisenatide alone \[[@CR13], [@CR14], [@CR23]\]. iGlarLixi, given as a once-daily subcutaneous injection, has been shown to reduce the incidence of common AEs associated with lixisenatide, such as nausea and vomiting. This is likely to be related to the more gradual titration of lixisenatide in iGlarLixi, which runs parallel to the up-titration of insulin. Moreover, safety data of the individual components of iGlarLixi have shown no increased risk of cardiovascular disease, thyroid cancer, pancreatitis, or pancreatic malignancy. In addition to offering comparable safety and reduced AEs, combination therapies are generally considered to be a more convenient alternative to taking the individual components separately, providing simpler treatment regimens with fewer daily injections.
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